8-K: Tenax Therapeutics Secures $25 Million Private Placement to Advance Phase 3 Clinical Trials

Tenax Therapeutics announces a $25 million private placement to fund Phase 3 clinical trials and general corporate purposes, extending its cash runway through 2027.

Summary

• Tenax Therapeutics has entered into a securities purchase agreement for a $25 million private placement with RTW Investments.
• The private placement involves the issuance of 378,346 shares of common stock and pre-funded warrants to purchase 3,760,726 shares of common stock.
• The purchase price is $6.04 per share, while pre-funded warrants are priced at $6.03 with an exercise price of $0.01.
• The private placement is expected to close on March 5, 2025, pending customary closing conditions.
• Leerink Partners is the lead placement agent, joined by Guggenheim Securities and William Blair.
• The company plans to use the proceeds to advance Phase 3 clinical trials, for working capital, and for general corporate purposes.
• The proceeds, combined with existing cash, are expected to fund operations through the end of 2027.
• The pre-funded warrants are exercisable at any time and include beneficial ownership limitations.
• Tenax Therapeutics has agreed to file a registration statement for the resale of the shares and underlying shares within 45 days of closing.
• The company also announced the FDA has accepted an amendment to enlarge the Phase 3 LEVEL study and agreed to initiate a second global Phase 3 study, LEVEL-2, for TNX-103 (Oral Levosimendan) for the treatment of PH-HFpEF.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Tenax Therapeutics, driven by the successful private placement, FDA acceptance of clinical trial plans, and promising early data from the LEVEL study. The company's financial position is strengthened, and the development timeline for TNX-103 is accelerated, increasing the likelihood of a successful outcome.

Positives

• The $25 million private placement strengthens Tenax Therapeutics' financial position.
• The extended cash runway through 2027 provides financial stability for ongoing and planned clinical trials.
• Advancing Phase 3 clinical trials for TNX-103 could lead to a potential first therapy for PH-HFpEF.
• FDA acceptance of the LEVEL study amendment and agreement to initiate LEVEL-2 accelerates the development timeline.
• High rates of study and therapy continuation, the adherence to the TID regimen has been high, and no new safety signals have been detected.

Negatives

• The private placement involves the issuance of new shares, which may dilute existing shareholders.
• The company is dependent on the success of its Phase 3 clinical trials, which are subject to inherent risks and uncertainties.
• The cash estimate is a preliminary estimate and is based on information available to management as of the date of the Private Placement, and these estimates could change.

Risks

• Market conditions and satisfaction of closing conditions related to the private placement could impact the financing.
• Clinical trials are subject to delays, design changes, and unexpected costs.
• Regulatory review and approval of product candidates are not guaranteed.
• The company relies on third parties, including manufacturers and CROs, which introduces potential risks.
• The company's estimates regarding the potential market opportunity for its product candidates may not be accurate.
• The company may face challenges in maintaining its culture and recruiting and retaining qualified personnel.
• The company faces competition from other companies developing therapies for cardiopulmonary diseases.
• Global economic and financial market volatility could impact the company's operations and financial performance.

Future Outlook

Tenax Therapeutics expects the private placement proceeds, combined with existing cash, to fund operations through the end of 2027. The company plans to advance its Phase 3 clinical trials for TNX-103 and anticipates presenting topline data from the LEVEL study in the middle of 2026. The company also expects to commence the global LEVEL-2 study later this year.

Management Comments

• 'We are increasing our investment in the clinical development plan for TNX-103 by expanding the ongoing LEVEL study and accelerating our plans to initiate the second registrational study, LEVEL-2,' said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics.
• 'LEVEL is enrolling well: we are confident that, with more than 50 North American sites already activated, we can complete enrollment of this upsized study around year end, while also commencing the global LEVEL-2 study later this year,' said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics.
• 'We expect these two registrational studies will satisfy the requirements, including the safety data expectations, to file in the U.S. and other geographies,' said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics.
• 'We are funded well beyond our projected date for the release of topline LEVEL data, positioning us to advance the development of TNX-103 and improve the quality of life for patients living with PH-HFpEF,' said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics.
• 'In addition to high rates of study and therapy continuation, the adherence to the TID regimen has been high, and no new safety signals have been detected,' said Stuart Rich, MD, Tenax Therapeutics Chief Medical Officer.
• 'TNX-103 has the potential to meaningfully improve the quality of life of patients with PH-HFpEF, an underdiagnosed disease with significant unmet needs and no currently approved treatment options,' said Dr. Rich.
• 'I remain very hopeful that with positive Phase 3 results, these patients will finally have an approved treatment available,' said Dr. Rich.
• 'We are continuing to work closely with the FDA, and are grateful for their input, which enables Tenax to accelerate development timelines of a potential first therapy for this devastating form of PH,' said Dr. Rich.

Industry Context

This announcement comes as the pharmaceutical industry continues to focus on developing novel therapies for cardiopulmonary diseases, particularly those with significant unmet needs like PH-HFpEF. The successful completion of Phase 3 trials and subsequent regulatory approval could position Tenax Therapeutics as a key player in this therapeutic area.

Comparison to Industry Standards

• The decision to expand the LEVEL study to 230 patients and initiate the LEVEL-2 study reflects a commitment to generating robust clinical data, aligning with industry best practices for Phase 3 trials.
• The company's focus on PH-HFpEF, a disease with no currently approved treatment options, positions it to potentially capture a significant market share if TNX-103 proves effective.
• The company's approach to working closely with the FDA and incorporating their feedback into the clinical development plan is consistent with industry standards for regulatory engagement.
• Comparable companies in the cardiopulmonary space include Actelion Pharmaceuticals (acquired by Johnson & Johnson), United Therapeutics, and Bayer, all of which have invested heavily in developing and commercializing therapies for pulmonary hypertension and heart failure.
• The company's timeline for completing enrollment in the LEVEL study by the end of 2025 and presenting topline data in the middle of 2026 is consistent with typical timelines for Phase 3 clinical trials in the pharmaceutical industry.

Stakeholder Impact

• Shareholders: The private placement provides financial stability and supports the advancement of clinical trials, potentially increasing shareholder value.
• Employees: The financing enables the company to continue its operations and development programs, providing job security and growth opportunities.
• Patients: The development of TNX-103 could lead to a new treatment option for PH-HFpEF, improving their quality of life.
• Investors: The private placement offers an opportunity to invest in a company with a promising pipeline and a clear development plan.

Next Steps

• Close the private placement transaction.
• File a registration statement with the SEC for the resale of shares and underlying shares.
• Enroll 230 patients in the LEVEL study and complete enrollment around year end 2025.
• Commence the global LEVEL-2 study in 2025.
• Present topline data from the LEVEL study in the middle of 2026.

Key Dates